Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (September 2015)
25 slides from Inspiremd's investor presentation, Sep 9, 2015
Slide 1: InspireMD September 2015
NYSE MKT: NSPR September 2015
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains "forward - looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward -
Slide 3: Emerging medical device company overview
3 An emerging medical device company developing and commercializing advanced technology for interventional cardiology and other vascular procedures InspireMD NYSE MKT: NSPR Stock Price (9/4/15): $0.19 52 Week Range: $0.18 - $2.44 Average Volume: 1,122K Shares Outstanding (9/4/15): 78 M Market Capita
Slide 4: Investment Highlights
Investment Highlights 4 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuro and Peripher
Slide 5: InspireMD stents press coverage
inspireMD Stents Boost Stroke EEO uudy Finds eens The IBM Cloud
Slide 6: Leadership: Significant Track Records of Success
6 Leadership: Significant Track Records of Success EXECUTIVE TEAM BOARD OF DIRECTORS Alan Milinazzo, President, CEO & Director • Medtronic • Boston Scientific Craig Shore, CFO • Pfizer • General Electric Dr. James Barry, COO • Boston Scientific • Howmedica Division of Pfizer Eli Bar, CTO • Nicast Gw
Slide 7: Technology: MicroNet
Technology: MicroNet ™ 7 Proprietary MicroNet Mesh for Embolic Prevention and Flow Diversion MicroNet Platform Ultra thin PET enhances clinical benefit of scaffold devices • Provides revascularization benefit • MicroNet acts as safety net by offering greater surface area coverage to prevent large de
Slide 8: Large Addressable Markets Expanding the MicroNet Platform
Large Addressable Markets 8 Expanding the MicroNet ™ Platform MGuard ™ x $1.7B Market x CE Mark Cleared x Coronary AMI, SVG CGuard ™ x $500M Market x CE Mark Cleared x Carotid NVGuard x $125M Flow Diversion Market x $550M Aneurysm Market x 2016E CE Mark Planned Submission for Flow Diverter x Neurova
Slide 9: Carotid Market Opportunity
Carotid Market Opportunity 9 An Enhanced Minimally Invasive Solution • Standard of care: Open surgery: Carotid EndArterectomy (CEA) • Current stents have not improved on CEA stroke rates (CREST) • Mesh covered stent category has the potential to convert CEA to CAS • CARENET 30 - day and 6 - mo data
Slide 10: Carotid Solution Emerging Market Opportunity
Carotid Solution 10 Emerging Market Opportunity CGuard ™ Embolic Prevention System Combines stent and embolic protection in a single device • CE marked • Self - expanding nitinol stent • Global market valued at $500M* • Strong CARENET FIM data released 9/14 and 1/15 • Impressive all - comer data fro
Slide 11: Positive CGuard Clinical Experience: CARENET
Positive CGuard™ Clinical Experience 11 * FIM , First in Man CARENET ( CAR otid E mbolic protection using micro NET ) FIM* Clinical Trial • 30 Patient Safety and Efficacy clinical trial • Prospective, multi - center, multispecialty, non - randomized single arm study • DWMRI follow ups at 48hrs and 3
Slide 12: Positive CGuard Clinical Experience: PARADIGM
Positive CGuard™ Clinical Experience 12 * FIM , First in Man PARADIGM ( P rospective evaluation of A ll - comer pe rR cutaneous c A roti D revascularization I n symptomatic and increased - risk asymptomatic carotid artery stenosis using C G uard TM M esh - covered embolic prevention system) Physicia
Slide 13: Strategic Distribution Partnership
Strategic Distribution Partnership 13 • Founded in 2005 as a Neurovascular company with a clinically - driven product development strategy • Reputation as the innovation leader in the neurovascular field • Extending success beyond stroke into the periphery and neurosurgical markets • Track record of
Slide 14: Commercial Profile: Revenue Growth Driven by CGuard RX
- 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Q1 Q2 Q3 Q4 2012 2013 2014 2015 Commercial Profile 14 Revenue Growth Driven by CGuard ™ RX • Late September 2015: Full Total Systems Solution Launch • Key European Territories Targeted • Opportunity to Increase Number of Target Territories Note: Revenu
Slide 15: Robust Pipeline
Robust Pipeline 15 Commercial • CE Mark Cleared • 12 - month MASTER I, II MicroNet ™ Platform Technology MGuard ™ Coronary EPS NVGuard ™ Neurovascular* RGuard™ Renal * CGuard ™ RX Carotid PVGuard™ Peripheral * MGuard ™ Drug Eluting * * Planning & Development Phase Commercial • CE Mark Cleared •
Slide 16: Neurovascular Market Opportunity
Neurovascular Market Opportunity 16 Innovation Leads Growth • Current designs have sub - optimal trackability and in vessel flexibility: metal on metal devices • MicroNet has proven flow diversion effect with ultra low profile and improves device flexiblity to improve device deliverability Source: M
Slide 17: NVGuard Neurovascular Differentiation
NVGuard ™ Neurovascular 17 Differentiation Yields Increased Utility Our Significant Advantage Over Existing Flow Diverters • MicroNet aperture & size • Low metal to artery ratio • Can be placed in side branches and bifurcations, which is impossible with current technology Total Aneurysm Market Value
Slide 18: Neurovascular Market
Neurovascular Market 18 • Medtronic acquires Medina Medical for $150 million • Stryker Acquires Surpass Medical for $135 million • Covidien Acquires Chestnut Medical for $150 million * * Based on milestones achieved as part of structured deal High Strategic interest with attractive valuations
Slide 19: Intellectual Property Portfolio
Intellectual Property Portfolio 19 Continue to strengthen and broaden patent protection globally. Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products Source: MRG PATENT RIGHTS Issued Allowed Pending US 2 2 10 Rest of Wor
Slide 20: Target Milestones
2015E 2016E 2017E R&D/ Clin / Reg Corporate Operational Commercial Target Milestones 20 Support & Execute on Growth Initiatives Strategic Partnership : Penumbra Strategic Partnership V Strategic Partnership IV DES Estimated CE Mark Achieve Targeted COGS NVGuard CE Mark Submission CGuard RX Launch NV
Slide 21: Investment Highlights
Investment Highlights 21 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuro and Periphe
Slide 22: Contact Details
Alan Milinazzo , CEO (888) 776 - 6804 alanm@ inspiremd.com Craig Shore, CFO (888) 776 - 6804 craigs@inspiremd.com
Slide 23: Coronary MGuard EPS
Coronary MGuard ™ EPS 23 Improving AMI Patient Outcomes • Current stents not specifically designed for AMI • Distal embolization occurs in up to 73% of cases* • Majority of AMI market is outside of the U.S . (~ 60%) • MGuard clinical experience including two randomized trials MASTER I and MASTER II
Slide 24: MASTER I & II Pooled: All Cause Mortality
24 MASTER I & II Pooled: All Cause Mortality at 30 days (743 patients) 0 5 10 15 20 25 30 Time in Days BMS/DES (n=371) MGuard (n=372) 5 4 3 2 1 0 Death (%) HR: 0.14 [95% CI: 0.02, 1.15] P=0.03 1.9% 0.3%
Slide 25: PVGuard Peripheral
PVGuard™ Peripheral Inspi reMD Enabling a New Solution: Peripheral Embolic Protection The Embolic Prevention System Anew stent category as the preferred solution for peripheral intervention Global Peripheral Stenting - $1.78 us + Current stents not specifically designed for embolic om protection + M